Chemical carcinogenesis

Anais da Academia Brasileira de Ciencias

Volumn 79, Issue 4, 2007, Pages 593-916

  Oliveira, Paula A ^a   Colaço, Aura ^a   Chaves, Raquel ^b   Guedes Pinto, Henrique ^b   De La Cruz, Luis F P ^c   Lopes, Carlos ^d,e  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

Cancer stages; Carcinogenesis evaluation; Chemical carcinogenesis; Chemical carcinogens

Indexed keywords

ANIMALIA;

EID: 37049038223     PISSN: 00013765     EISSN: 16782690     Source Type: Journal    
DOI: 10.1590/s0001-37652007000400004     Document Type: Article

References (166)

1. ACHANZAR WE, BRAMBILA EM, DIWAN BA, WEBBER MM AND WAALKE S MP. 2002. Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J Natl Cancer Inst 94: 1888-1891.
2. ADIMOOLAM S AND FORD JM. 2002. p53 and DNA damageinducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci USA 99: 12985-12990.
3. AIROLDI L, PASTORELLI R, MAGAGNOTTI C AND FANELLI R. 1999. Carcinogen-DNA adducts as tools in risk assessment. Adv Exp Med Biol 472: 231-240.
4. AMES BN. 1984 The detection of environmental mutagens and potential carcinogens. Cancer 53: 2034-2040.
5. ASHBY J. 1996. Prediction of Rodent Carcinogenicity for 30 Chemicals. Environ Health Perspect 104S: 1101-1104.
6. BABENKO VN, BASU MK, KONDRASHOV FA, ROGOZIN IB AND KOONIN EV. 2006. Signs of positive selection of somatic mutations in human cancers detected by EST sequence analysis. BMC Cancer 9: 26-36.
7. BAIRD WM AND MAHADEVAN B. 2004. The uses of carcinogen-DNA adduct measurement in establishing mechanisms of mutagenesis and in chemoprevention. Mutat Res 547: 1-4.
8. BALMAIN A AND HARRIS CC. 2000. Carcinogenesis in mouse and human cells: parallels and paradoxes. Carcinogenesis 21: 371-377.
9. BARRATT MD AND RODFORD RA. 2001. The computational prediction of toxicity. Opin Chem Biol 5: 383-388.
10. BARRETT JC. 1993. Mechanisms of multistep carcinogenesis and carcinogen risk assessment. Environ Health Perspect 100: 9-20.
11. BARRETT JC AND ANDERSON M. 1993. Molecular mechanisms of carcinogenesis in humans and rodents. Mol Carcinog 7: 1-13.
12. BARRET JC AND WISEMAN RW. 1987. Cellular and molecular mechanisms of multistep carcinogenesis: relevance to carcinogen risk assessment. Environ Health Perspect 76: 65-70.
13. BARTSCH H AND HIETANEN E. 1996. The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 104: 569-577.
14. BEREMBLUM I AND SHUBIK P. 1947. The role of croton oil applications, associated with a single painting of a carcinogen, in tumor induction of the mouse's skin. Br J Cancer 1: 379-382.
15. BERTRAM JS. 2001. The molecular biology of cancer. Mol Aspects Med 21: 167-223.
16. BLAGOSKLONNY MV. 2005. Molecular theory of cancer. Cancer Biol Ther 4: 621-627.
17. BOLT HM, FOTH H, HENGSTLER JG AND DEGEN GH. 2004. Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective. Toxicol Lett 151: 29-41.
18. BONDY M. 2004. Estimated risk in malignancy: the emerging field of molecular epidemiology. Clin Adv Hematol Oncol 2: 147-151.
19. BONNET JL, DUSSER M, BOHATIER J AND LAFFOSSE J. 2003. Cytotoxic assessment of three therapeutic agents, cyclosporine-A, cisplatin and doxorubicin, with the ciliated protozoan Tetrahymena pyriformis. Res Microbiol 154: 375-385.
20. BUTTERWORTH BE AND BOGDANFFY MS. 1999. A comprehensive approach for integration of toxicity and cancer risk assessments. Regul Toxicol Pharmacol 29: 23-36.
21. BUTTERWORTH BE, POPP JA, CONOLLY RB AND GOLDSWORTHY TL. 1992. Chemically induced cell proliferation in carcinogenesis. IARC Sci Publ 116: 279-305.
22. BUTTERWORTH BE, TEMPLIN MV, CONSTAN AA, SPRANKLE CS, WONG BA, PLUTA LJ, EVERITT JI AND RECIO L. 1998. Long-term mutagenicity studies with chloroform and dimethylnitrosamine in female lad transgenic B6C3F1 mice. Environ Mol Mutagen 31: 248-56.
23. CAMARGO JLV, SALVADORI DMF, ROCHA NS, BAEBISAN LF AND RIBEIRO LR. 1999. The detection of chemical carcinogens in an alternative medium-term bioassay. J Braz Ass Advan Science 51: 22-26.
24. CARRIER F ET AL. 1999. Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin. Mol Cell Biol 19: 1673-1685.
25. CHAO EC AND LIPKIN SM. 2006. Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesis. Nucleic Acids Research 34: 840-852.
26. COHEN SM. 1991. Analysis of modifying factors in chemical carcinogenesis. Prog Exp Tumor Res 33: 21-40.
27. COHEN SM. 1995. Role of urinary physiology and chemistry in bladder carcinogenesis. Food Chem Toxicol 33: 715-730.
28. COHEN SM. 1998. Cell proliferation and carcinogenesis. Drug Metab Rev 30: 339-357.
29. COHEN SM AND ELLWEIN LB. 1991. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res 51: 6493-6505.
30. COHEN SM AND LAWSON TA. 1995. Rodent bladder tumors do not always predict for humans. Cancer Lett 93: 9-16.
31. COHEN SM, PURTILO DT AND ELLWEIN LB. 1991. Ideas in pathology. Pivotal role of increased cell proliferation in human carcinogenesis. Mod Pathol 4: 371-382.
32. COHEN SM, GARLAND EM AND ELLWEIN LB. 1992. Cancer enhancement by cell proliferation. Prog Clin Biol Res 374: 213-229.
33. CONNOLY RB, REITZ RH, CLEWELL 3RD HJ AND ANDERSON ME. 1988. Pharmacokinetics, biochemical mechanism and mutation accumulation: a comprehensive model of chemical carcinogenesis. Toxicol Lett 43: 189-200.
34. COSTA M, YAN Y, ZHAO D AND SALNIKOW K. 2003. Molecular mechanisms of nickel carcinogenesis: gene silencing by nickel delivery to the nucleus and gene activation/inactivation by nickel-induced cells signalling. J Environ Monit 5: 222-223.
35. DEWHIRST MW, LORA-MICHIELS M, VIGLIANTI BL, DEWEY WC AND REPACHOLI M. 2003. Carcinogenic effects of hyperthermia. Int J Hyperthermia 19: 236-251.
36. DIXON K AND KOPRAS E. 2004. Genetic alterations and DNA repair in human carcinogenesis. Semin Cancer Biol 14: 441-448.
37. DRABLOS F ET AL. 1998. Studies of initiation and promotion of carcinogenesis by N-nitroso compounds. Cancer Lett 123: 185-191.
38. DYBDAHL M, FRENTZ G, VOGEL U, WALLIN H AND NEXO BA. 1999. Low DNA repair is a risk factor in skin carcinogenesis: a study of basal cell carcinoma in psoriasis patients. Mutat Res 433: 15-22.
39. DYBING E AND SANNER T. 1999. Species differences in chemical carcinogenesis of the thyroid gland, kidney and urinary bladder. IARC Sci Publ 147: 15-32.
40. FARBER E. 1984. The multi-step nature of cancer development. Cancer Res 44: 4217-4223.
41. FARMER PB. 1994. Carcinogen adducts: use in diagnosis and risk assessment. Clin Chem 40: 1438-1443.
42. FENG J, LURATI L, OUYANG H, ROBINSON T, WANG Y, YUAN S AND YOUNG SS. 2003. Predictive toxicology: benchmarking molecular descriptors and statistical methods. J Chem Inf Comput Sci 43: 1463-1470.
43. FLORES-ROZAS H, CLARK D AND KOLODNER RD. 2000. Proliferating cell nuclear antigen and Msh2p-Msh6p interact to form an active mispair recognition complex. Nat Genet 26: 375-378.
44. FOULDS L. 1954. The experimental study of tumor progression: a review. Cancer Res 14: 327-339.
45. FRIEDBERG EC. 2003. DNA damage and repair. Nature 421: 436-440.
46. FROWEIN J. 2000. Hypothesis: chemical carcinogenesis mediated by a transiently active carcinogen receptor. Cytogenet Cell Genet 91: 102-104.
47. GALATI G, TENG S, MORIDANI MY, CHAN TS AND O'BRIEN PJ. 2000. Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug Metabol Drug Interact 17: 311-349.
48. GARCEA G, DENNISON AR, STEWARD WP AND BERRY DP. 2003. Chemoprevention of gastrointestinal malignancies. ANZ J Surg 73: 680-686.
49. GARNER RC. 1998. The role of DNA adducts in chemical carcinogenesis. Mutat Res 402: 67-75.
50. GAYLORDWANDCHEN JJ. 1986. Relative potency of chemical carcinogens in rodents. Risk Anal 6: 283-290.
51. GOLKA K, KOPPS S AND MYSLAK ZW. 2004. Carcinogenicity of azo colorants: influence of solubility and bioavailability. Toxicol Lett 151: 203-210.
52. GOMES-CARNEIRO MR, RIBEIRO-PINTO LF AND PAUMGARTTEN FJ. 1997. Environmental risk factors for gastric cancer: the toxicologist's standpoint. Cad Saúde Pública 13 (Suppl): 27-38.
53. GONZALEZ FJ. 2001. The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. Toxicol Lett 120: 199-208.
54. GONZALEZ FJ AND KIMURA S. 2001. Understanding the role of xenobiotic-metabolism in chemical carcinogenesis using gene knockout mice. Mutat Res 477: 79-87.
55. GRISHAM JW, KAUFMANN WK AND KAUFMAN DG. 1984. The cell cycle and chemical carcinogenesis. Surv Synth Patho Res 1: 49-66.
56. GUENGERICH FP. 2000. Metabolism of chemical carcinogens. Carcinogenesis 21: 345-351.
57. GUENGERICH FP. 2001. Forging the links between metabolism and carcinogenesis. Mutat Res 488: 195-209.
58. GUITTET O, HAKANSSON P, VOEVODSKAYA N, FRIDD S, GRASLUND A, ARAKAWA H, NAKAMURA Y AND THELANDER L. 2001. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 276: 40647-40651.
59. GUTIÉRREZ JB AND SALSAMENDI AL. 2001. Fundamientos de ciência toxicológica. Diaz de Santos, Madrid, p. 155-177.
60. HANAHAN D AND WEINBERG RA. 2000. The hallmarks of cancer. Cell 100: 57-70.
61. HANAWALT PC, FORD JM AND LLOYD DR. 2003. Functional characterization of global genomic DNA repair and its implications for cancer. Mutat Res 544: 107-114.
62. HARMS K, NOZELL S AND CHEN X. 2004. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 61: 822-842.
63. HARTWIG A, ASMUSS M, EHLEBEN I, HERZER U, KOSTELAC D, PELZER A, SCHWERDTLE T AND BURKLE A. 2002. Interference by toxic metal ions with DNA repair processes and cell cycle control: molecular mechanisms. Environ Health Perspect 110 (Suppl 5): 797-799.
64. HASEGAWA R, FUTAKUCHI M, MIZOGUCHI Y, YAMAGUCHI T, SHIRAI T, ITO N AND LIJINSKY W. 1998. Studies of initiation and promotion of carcinogenesis by N-nitroso compounds. Cancer Lett 123: 185-191.
65. HASEMAN J, MELNICK R, TOMATIS L AND HUFF J. 2001. Carcinogenesis bioassays: study duration and biological relevance. Food Chem Toxicol 39: 739-744.
66. HAWIGHORST T, VELASCO P, STREIT M, HONG YK, KYRIAKIDES TR, BROWN LF, BORNSTEIN P AND DETMAR M. 2001. Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J 20: 2631-2640.
67. HAYES RB. 1995. Genetic susceptibility and occupational cancer. Med Lav 86: 206-213.
68. HAYES JD AND PULFORD DJ. 1995. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30: 445-600.
69. HEIDELBERGER C. 1977. Chemical carcinogenesis. Cancer 40: 430-433.
70. HENGSTLER JG, ARAND M, HERRERO ME AND OESCH F. 1998. Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Recent Results Cancer Res 154: 47-85.
71. HUFF J. 1992. Chemical toxicity and chemical carcinogenesis. Is there a causal connection? A comparative morphological evaluation of 1500 experiments. IARC Sci Pub 116: 437-475.
72. HUFF J. 1994. Chemicals causally associated with cancers in humans and in laboratory animals. A perfect concordance. In: WALLACE MP AND WARD JM (Eds), Carcinogenesis, Raven Press, Ltd., New York, p. 25-37.
73. HUFF J. 1999. Chemicals associated with tumours of the kidney, urinary bladder and thyroid gland in laboratory rodents from 2000 US National Toxicology Program / National Cancer Institute bioassays for carcinogenicity. IARC Sci Pub 147: 211-225.
74. HWANG BJ, FORD JM, HANAWALT PC AND CHU G. 1999. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sei USA 96: 424-428.
75. ISHIKAWA T, IDE F, QIN X, ZHANG S, TAKAHASHI Y, SEKIGUCHI M, TANAKA K AND NAKATSURU Y. 2001. Importance of DNA repair in carcinogenesis: evidence from transgenic and gene targeting studies. Mutat Res 477: 414-419.
76. ITO N, SHIRAI T AND HASEGAWA R. 1992. Medium-term bioassays for carcinogens. IARC Sci Publ 116: 353-388.
77. JENG JH, CHANG MC AND HAHN LJ. 2001. Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives. Oral Oncol 37: 477-492.
78. KHAN QA AND DIPPLE A. 2000. Diverse chemical carcinogens fail to induce G(1) arrest in MCF-7 cells. Carcinogenesis 21: 1611-1618.
79. KHAN QA, VOUSDEN KH AND DIPPLE A. 1999. Lack of p53-mediated G1 arrest in response to an environmental carcinogen. Oncology 57: 258-264.
80. KING C, WANG C, GORELICK N AND FREDERICK C. 1995. Genotoxicity in the rodent urinary bladder. Food Chem Toxicol 33: 757-769.
81. KINZLER KW AND VOGELSTEIN B. 1997. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386: 761-763.
82. KLAUNIG JE, KAMENDULIS LM AND XU Y 2000. Epigenetic mechanisms of chemical carcinogenesis. Hum Exp Toxicol 19: 543-555.
83. KOIVUSALO M, JAAKKOLA JJ, VARTIAINEN T, HAKULINEN T, KARJALAINEN S, PUKKALA E AND TUOMISTO J. 1994. Drinking water mutagenicity and gastrointestinal and urinary tract cancers: an ecological study in Finland. Am J Public Health 84: 1223-1228.
84. LAI C AND SHIELDS PG. 1999. The role of interindividual variation in human carcinogenesis. J Nutr 29: 552S-555S.
85. LAMERS MH, PERRAKIS A, ENZLIN JH, WINTERWERP HH, WIND N AND SIXMA TK. 2000. The crystal structure of DNA mismatch repair protein MutS binding to a G x T mismatch. Nature 407: 711-717.
86. LI H, UNG CY, YAP CW, XUE Y, LI ZR, CAO ZW AND CHEN YZ. 2005. Prediction of genotoxicity of chemical compounds by statistical learning methods. Chem Res Toxicol 18: 1071-1080.
87. LOCK EA, REED CJ, MCMILLAN JM, OATIS JE JR AND SCHNELLMANN RG. 2007. Lack of formic acid production in rat hepatocytes and human renal proximal tubule cells exposed to chloral hydrate or trichloroacetic acid. Toxicology 230: 234-243.
88. LOEB LA. 1998. Cancer cells exhibit a mutator phenotype. Adv Cancer Res 72: 25-56.
89. LOEW GH, POULSEN M, KIRKJIAN E, FERRELL J, SUDHINDRA BS AND REBAGLIATI M. 1985. Computer-assisted mechanistic structure-activity studies: application to diverse classes of chemical carcinogens. Environ Health Perspect 61: 69-96.
90. LUCH A. 2005. Nature and nurture - lessons from chemical carcinogenesis. Nat Rev Cancer 5: 113-125.
91. LUTZ WK. 1998. Dose-response relationships in chemical carcinogenesis: superposition of different mechanisms of action, resulting in linear-nonlinear curves, practical thresholds, J-shapes. Mutat Res 405: 117-124.
92. LUTZ WK. 1999. Dose-response relationships in chemical carcinogenesis reflect differences in individual susceptibility. Consequences for cancer risk assessment, extrapolation, and prevention. Hum Exp Toxicol 18: 707-712.
93. LUTZ WK. 2000. A true threshold dose in chemical carcinogenesis cannot be defined for a population, irrespective of the mode of action. Hum Exp Toxicol 19: 566-568.
94. LUTZ WK. 2001. Susceptibility differences in chemical carcinogenesis linearize the dose-response relationship: threshold doses can be defined only for individuals. Mutat Res 482: 71-76.
95. LUTZ WK. 2002. Differences in individual susceptibility to toxic effects of chemicals determine the dose-response relationship and consequences of setting exposure standards. Toxicol Lett 126: 155-158.
96. MARONPOT RR. 1996. A symposium summary and perspective on comparative molecular biology of cancer. Toxicol Pathol 24: 801-814.
97. MARONPOT RR AND BOORMAN GA. 1996. The contribution of the mouse in hazard identification studies. Toxicol Pathol 24: 726-731.
98. MASTERS JR. 2000. Human cancer cell lines: fact and fantasy. Nat Rev Mol Cell Biol 1: 233-236.
99. MEHTA R. 1995. The potential for the use of cell proliferation and oncogene expression as intermediate markers during liver carcinogenesis. Cancer Lett 93: 85-102.
100. MELNICK RL, HUFF J, BARRETT JC, MARONPOT RR, LUCIER G AND PORTIER CJ. 1993. Cell proliferation and chemical carcinogenesis: symposium overview. Environ Health Perspect 101: 3-7.
101. MELNICK RL, KOHN MC AND PORTIER CJ. 1996. Implications for risk assessment of suggested non-genotoxic mechanisms of chemical carcinogenesis. Environ Health Perspect 104: 123-134.
102. MILLER EC AND MILLER JA. 1952. In vivo combinations between carcinogens and tissue constituints and their possible role in carcinogenesis. Cancer Res 12: 547-556.
103. MILLER JA AND MILLER EC. 1975. Metabolic activation and reactivity of chemical carcinogens. Mutat Res 33: 25-26.
104. MILLER 3RD MC, MOHRENWEISER HW AND BELL DA. 2001. Genetic variability in susceptibility and response to toxicants. Toxicol Lett 120: 269-280.
105. MINAMOTO T, MAI M AND RONAI Z. 2000. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers-a review. Cancer Detect Prev 24: 1-12.
106. MIRSALIS JC, STEINMETZ KL, HAMILTON CM, BAKKE JP AND GARIN KE. 1990. The role of cell proliferation in chemical carcinogenesis. Prog Clin Biol Res 340: 113-122.
107. MOSTAFA MH, SHEWEITA SA AND O'CONNOR PJ. 1999. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev 12: 97-111.
108. MOUSTACCHI E. 1998. [Molecular mechanisms of carcinogenesis: the role of systems of DNA repair]. Bull Acad Natl Med 182: 33-46.
109. NAKANO K, BALINT E, ASHCROFT M AND VOUSDEN KH. 2000. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 19: 4283-4289.
110. NGUYEN-BA G AND VASSEUR P. 1999. Epigenetic events during the process of cell transformation induced by carcinogens (review). Oncol Rep 6: 925-932.
111. ODA Y. 2004. Analysis of the involvement of human N-acetyl-transferase 1 in the genotoxic activation of bladder carcinogenic arylamines using a SOS/umu assay system. Mutat Res 554: 399-406.
112. OESCH F, HERRERO ME, HENGSTLER JG, LOHMANN M AND ARAND M. 2000. Metabolic detoxification: implications for thresholds. Toxicol Pathol 28: 382-387.
113. OHSHIMA H, TATEMICHI M AND SAWA T. 2003. Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 417: 3-11.
114. OHSHIMA H, TAZAWA H, SYLLA BS AND SAWA T. 2005. Prevention of human cancer by modulation of chronic inflammatory processes. Mutat Res 591: 110-122.
115. OTTENEDER M AND LUTZ WK. 1999. Correlation of DNA adduct levels with tumor incidence: carcinogenic potency of DNA adducts. Mutat Res 424: 237-247.
116. PARK BK, KITTERINGHAM NR, MAGGS JL, PIRMOHAMED M AND WILLIAMS DP. 2005. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 45: 177-202.
117. PAYNE SR AND KEMP CJ. 2003. p27(Kip1) (Cdkn1b)-deficient mice are susceptible to chemical carcinogenesis and may be a useful model for carcinogen screening. Toxicol Pathol 31: 355-363.
118. PITOT HC. 2001. Animal models of neoplastic development. Dev Biol (Basel) 106: 53-57.
119. PITOT HC AND DRAGAN YP. 1991. Facts and theories concerning the mechanisms of carcinogenesis. FASEB J 5: 2280-2286.
120. PLAYER A, BARRETT JC AND KAWASAKI ES. 2004. Laser capture microdissection, microarrays and the precise definition of a cancer cell. Expert Rev Mol Diagn 4: 831-840.
121. POIRIER MC, SANTELLA RM AND WESTON A. 2000. Carcinogen macromolecular adducts and their measurement. Carcinogenesis 21: 353-359.
122. th Walter Hubert Lecture. Br J Cancer 38: 1-23.
123. PRITCHARD JB, FRENCH JE, DAVIS BJ AND HASEMAN JK. 2003. The role of transgenic mouse models in carcinogen identification. Environ HealthPerspect 111: 444-454.
124. QU W, BORTNER CD, SAKURAI T, HOBSON MJ AND WAALKES MP. 2002. Acquisition of apoptotic resistance in arsenic-induced malignant transformation: role of the JNK signal transduction pathway. Carcinogenesis 23: 151-159.
125. RICHARDSON FC, BOUCHERON JA, DYROFF MC, POPP JA AND SWENBERG JA. 1986. Biochemical and morphologic studies of heterogeneous lobe responses in hepatocarcinogenesis. Carcinogenesis 7: 247-251.
126. th ed., Philadelphia: Elsevier Saunders, p. 319-323.
127. ROJAS M, CASCORBI I, ALEXANDROV K, KRIEK E, AUBURTIN G, MAYER L, KOPP- SCHNEIDER A, ROOTS I AND BARTSCH H. 2000. Modulation of benzo[a]pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. Carcinogenesis 21: 35-41.
128. SANTELLA RM, GAMMON M, TERRY M, SENIE R, SHEN J, KENNEDY D, AGRAWAL M, FARAGLIA B AND ZHANG F. 2005. DNA adducts, DNA repair genotype/phenotype and cancer risk. Mutat Res 592: 29-35.
129. SARASIN A AND MEUNIER-ROTIVAL M. 1976. How chemicals may induce cancer. Biomedicine 24: 306-316.
130. SCHERER SJ, MAIER SM, SEIFERT M, HANSELMANN RG, ZANG KD, MULLER-HERMELINK HK, ANGEL P, WELTER C, SCHARTL M. 2000. p53 and c- Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV. J Biol Chem 275: 37469-37473.
131. SCHMAHLD. 1976. Combination effects in chemical carcinogenesis (experimental results). Oncology 33: 73-76.
132. SCHUT HA AND CASTONGUAY A. 1984. Metabolism of carcinogenic amino derivatives in various species and DNA alkylation by their metabolites. Drug Metab Rev 15: 753-839.
133. SCOTT RE, WILLE JR JJ AND WIER ML. 1984. Mechanisms for the initiation and promotion of carcinogenesis: a review and a new concept. MayoClinProc59: 107-117.
134. SHACTER E AND WEITZMAN SA. 2002. Chronic inflammation and cancer. Oncology 6: 217-226.
135. SHARMA RA AND FARMER PB. 2004. Biological relevance of adduct detection of the chemopreventation of cancer. Clin Cancer Res 10: 4901-4912.
136. SHI H, HUDSON LG AND LIU KJ. 2004. Oxidative stress and apoptosis in metal ion-induced carcinogenesis. Free Radic Biol Med 37: 582-593.
137. SILLS RC, FRENCH JE AND CUNNINGHAM ML. 2001. New models for assessing carcinogenesis: an ongoing process. Toxicol Lett 120: 187-198.
138. SIMONS JW. 1995. Genetic, epigenetic, dysgenetic, and non-genetic mechanisms in tumorigenesis. Crit Rev Oncog 6: 261-273.
139. SIMONS JW. 1999. Genetic, epigenetic, dysgenetic and non-genetic mechanisms in tumorigenesis. II. Further delineation of the rate limiting step. Anticancer Res 19: 4781-4789.
140. SOBELS FH. 1975. Charlotte Auerbach and chemical mutagenesis. Mutation Res 29: 171-180.
141. STENBÄCK F, PETO R AND SHUBIK P. 1981. Initiation and promotion at different ages and doses in 2200 mice. I. Methods, and the apparent persistence of initiated cells. Br J Cancer 44: 1-14.
142. STRAUB KM AND BURLING AME AL. 1981. Carcinogen binding to DNA. Biomed Mass Spectrom 8: 431-435.
143. SWENBERG JA, FEDTKE N, CIROUSSEL F, BARBIN A AND BARTSCH H. 1992. Etheno adducts formed in DNA of vinyl chloride-exposed rats are highly persistent in liver. Carcinogenesis 13: 727-729.
144. TAN T AND CHU G. 2002. p53 Binds and activates the xeroderma pigmentosum DDB2 gene in humans but not mice. Mol Cell Biol 22: 3247-3254.
145. TENNANT RW. 1998. Evaluation and validation issues in the development of transgenic mouse carcinogenicity bioassays. Environ Health Perspect 106: 473-476.
146. TENNANT RW, FRENCH JE AND SPALDING JW. 1995. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect 103: 942-950.
147. TENNANT RW, STASIEWICZ S, MENNEAR J, FRENCH JE AND SPALDING JW. 1999. Genetically altered mouse models for identifying carcinogens. IARC Sei Publ 146: 123-150.
148. TOTH B. 2001. Species susceptibilities to chemical carcinogenes: a critical appraisal of the roles of genetic and viral agents. In Vivo 15: 467-478.
149. TROSKO JE. 2001. Commentary: is the concept of "tumor promotion" a useful paradigm? Mol Carcinog 30: 131-137.
150. TROSKO JE. 2003. The role of stem cells and gap junctional intercellular communication in carcinogenesis. J Biochem Mol Biol 36: 43-48.
151. TUFAN AC AND SATIROGLU-TUFAN NL. 2005. The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of anti-angiogenic agents. Curr Cancer Drug Targets 5: 249-266.
152. VAN LEEUWEN IM AND ZONNEVELD C. 2001. From exposure to effect: a comparison of modeling approaches to chemical carcinogenesis. Mutat Res 489: 17-45.
153. VOGELSTEIN B AND KINZLER KW. 2004. Cancer genes and the pathways they control. Nat Med 10: 789-799.
154. WADDELL WJ. 2002. Thresholds of carcinogenicity of flavors. Toxicol Sci 68: 275-279.
155. WANG TC, CHIOU CM AND CHANG YL. 1998. Genetic toxicity of N-methylcarbamate insecticides and their N-nitroso derivatives. Mutagenesis 13: 405-408.
156. WEINSTEIN IB. 1988. Strategies for inhibiting multistage carcinogenesis based on signal transduction pathways. Mutat Res 202: 413-420.
157. WEINSTEIN IB. 1991. Cancer prevention: recent progress and future opportunities Cancer Res 51: 5080-5085.
158. WEISBURGER JH. 1998. Worldwide prevention of cancer and other chronic diseases based on knowledge of mechanisms. Mutat Res 402: 331-337.
159. WEISBURGER JH. 1999. Carcinogenicity and mutagenicity testing, then and now. Mutat Res 437: 105-112.
160. WILD CP, GARNER RC, MONTESANO R AND TURSI F. 1986. Anatoxin B1 binding to plasma albumin and liver DNA upon chronic administration to rats. Carcinogenesis 7: 853-858.
161. WILLIAMS GM. 2001. Mechanisms of chemical carcinogenesis and application to human cancer risk assessment. Toxicology 161: 3-10.
162. XU J AND MORRIS GF. 1999. p53-mediated regulation of proliferating cell nuclear antigen expression in cells exposed to ionizing radiation. Mol Cell Biol 19: 12-20.
163. YAMAGIWA K AND ICHIKAWA K. 1918. Experimental study of the pathogenesis of carcinoma. J Cancer Res 3: 1-29.
164. YANG M AND SCHLUETER R. 2005. Molecular Epidemiology of Lung Cancer in Female Passive Smokers. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 23: 75-97.
165. YUSPA SH AND POIRIER MC. 1988. Chemical carcinogenesis: from animal models to molecular models in one decade. Adv Cancer Res 50: 25-70.
166. YUSPA SH, HENNINGS H, LICHTI U AND KULESZ-MARTIN M. 1983. Organ specificity and tumor promotion. Basic Life Sci 24: 157-171.